Results 51 to 60 of about 848 (166)
Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives. [PDF]
Exp DermatolABSTRACT JAK inhibitors are used to treat various inflammatory skin diseases. However, systemic formulations are associated with an increased risk of major adverse events. Ruxolitinib 1.5% cream is a selective topical JAK1 and JAK2 inhibitor, which has recently been approved by EMA and MHRA for treating non‐segmental vitiligo, while being FDA‐approved ...
Spadafora M +5 more
europepmc +2 more sources
Coexistence of scleromyxedema and Sneddon syndrome
, 2021 Coexistence of scleromyxedema and Sneddon ...
Antonio Furci +4 more
core +1 more source
Scleromyxedema with subclinical myositis [PDF]
, 2004 A 49-year-old farmer presented with papules on the face, arms, chest and back associated with sclerosis. Histopathology and PAS stain confirmed the clinical diagnosis of scleromyxedema. He also had elevated CPK levels due to myopathy.
Prasad PVS, Joseph Joe Mathew , Kaviarasan PK, Viswanathan P
core +3 more sources
Case Reports in Dermatology, 2013 Scleromyxedema is a rare cutaneous mucinosis, usually presenting with generalized papular eruption and sclerodermoid induration, monoclonal gammopathy and systemic manifestations.
M. Dolenc-Voljč +3 more
doaj +1 more source
Scleromyxedema in an HCV-positive male
, 2016 Scleromyxedema is rare chronic cutaneous mucinosis usually associated with a monoclonal gammopathy and underlying systemic disease. We report a 42-year-old male who developed scleromyxedema and was also HCV positive.
Tariq Zaman +3 more
core +1 more source
Scleromyxedema, a therapeutic dilemma
Indian Journal of Dermatology, 2015 Scleromyxedema is characterized by indurated erythematous papules disseminated on the face, chest and limbs. About twenty cases treated with thalidomide, stem cells, melphalan and immunoglobulin with varying results have been described.
Julio Cesar Salas-Alanis +3 more
doaj +1 more source
A Case with Resistant Scleromyxedema Responding to IVIG Treatment
, 2010 Scleromyxedema is a rare skin disease associated with paraproteinemia and characterized by the deposition of mucin in the skin. The pathogenesis of scleromyxedema is unknown.
Dilek BAYRAMGÜRLER +9 more
core +1 more source
Successful Treatment of Scleromyxedema with IVIG: A Case Report
Journal of Mazandaran University of Medical Sciences, 2018 Scleromyxedema (SM), a rare progressive cutaneous mucinosis with a systemic involvement, presents with progressive dermal mucin depositions, causing skin thickening.
Fatemeh Niksolat +5 more
doaj
Clinical Case Reports, Volume 13, Issue 12, December 2025.ABSTRACT Scleredema adultorum of Bushcke is a rare connective tissue disorder that is characterized by skin thickening that commonly starts from the neck and spreads to the face, shoulders, upper back, abdomen, and in some cases, thighs. The symptoms are generally seen after an infection associated with streptococcus.
Shabnam Hajiani Ghotbabadi +3 more
wiley +1 more source
Dermatology Reports, 2023 Scleromyxedema (SMX), the generalized and sclerodermic form of lichen myxedematous (LM), is a chronic mucinosis characterized by cutaneous manifestation and several systemic comorbidities.
Gaia Fasano +3 more
doaj +1 more source